Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
Kris Oliver JalusicDavid EllenbergerPaulus Stefan RommerAlexander StahmannUwe ZettlKlaus BergerPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2021)
The majority of MS patients treated in routine care would not have met clinical trials criteria. Thus, the efficacy and safety of therapies in clinical trials can differ from those in the real world. Broader phase III inclusion criteria would increase their eligibility and contribute to a better generalizability of the results in clinical trials.
Keyphrases
- clinical trial
- phase iii
- open label
- multiple sclerosis
- phase ii
- double blind
- healthcare
- palliative care
- end stage renal disease
- study protocol
- ejection fraction
- newly diagnosed
- placebo controlled
- mass spectrometry
- clinical practice
- quality improvement
- chronic kidney disease
- peritoneal dialysis
- pain management
- white matter
- ms ms
- tyrosine kinase